(Q38003195)

26 August 2017

title

Novel molecular targets for the therapy of urothelial carcinoma (English)

1 reference

26 August 2017

Bagi R P Jana

1

1 reference

26 August 2017

Matthew D Galsky

2

1 reference

26 August 2017

Noah M Hahn

3

1 reference

26 August 2017

Matthew I Milowsky

4

1 reference

26 August 2017

Guru Sonpavde

5

1 reference

26 August 2017

language of work or name

English

0 references

publication date

18 April 2012

1 reference

Expert Opinion on Therapeutic Targets

26 August 2017

published in

1 reference

26 August 2017

volume

16

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

499-513

1 reference

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

A request for nondisclosure: don't tell mother.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

The natural history of bladder cancer. Implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Cellular signaling by fibroblast growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Chromosomal changes in uroepithelial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Generation of a concise gene panel for outcome prediction in urinary bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Inactivation of p53 and Pten promotes invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Expression of basic fibroblast growth factor and its receptor in an invasive bladder carcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Phase II study of sunitinib in patients with metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Taming glioblastoma by targeting angiogenesis: 3 years later.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Targeting EGFR in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Targeting the HGF/Met signalling pathway in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Interdependent genotoxic mechanisms of monomethylarsonous acid: role of ROS-induced DNA damage and poly(ADP-ribose) polymerase-1 inhibition in the malignant transformation of urothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.677441

10.1517/14728222.2012.677441

21 January 2018

Identifiers

DOI

1 reference

release_acyhccumg5dfbjofifhhanxyuq

26 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/acyhccumg5dfbjofifhhanxyuq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference